Medetia Pharmaceuticals

Medetia is a French biotechnology company focused on developing first-in-class small molecule therapeutics for rare genetic diseases, specifically ciliopathies. The company utilizes a proprietary high-content phenotypic screening platform that employs patient-derived cells to identify compounds capable of restoring normal cellular function. Medetia's primary research focus is on orphan nephropathies, such as nephronophthisis, for which there are currently no approved disease-modifying treatments. By operating in close proximity to the Imagine Institute in Paris, the company bridges the gap between academic discovery and industrial drug development.